Affiliations: [a] Department of Stomatology, Area of Pathology, Bauru School of Dentistry, University of São Paulo, Bauru, Brazil | [b] Department of Computing, School of Sciences, São Paulo State University (UNESP), Bauru, Brazil | [c] Adolfo Lutz Institute, Pathology Division, São Paulo, Brazil | [d] Department of Head and Neck Surgery, Fundação Pio XII – Cancer Hospital of Barretos, Barretos, São Paulo, Brazil | [e] Department of Head and Neck Surgery and Otorhinolaryngology, Cancer Hospital A. C. Camargo, São Paulo, Brazil
Correspondence:
[*]
Address for correspondence: Denise Tostes Oliveira, Faculdade de Odontologia de Bauru, Área de Patologia, Alameda Octávio Pinheiro Brisolla, 9-75, CEP 17012-901, Bauru, São Paulo, Brazil. Tel.: +55 21 14 32358251; Fax: +55 21 14 32234679; E-mail: [email protected].
Abstract: The aim of this study was to evaluate the expression of β2-adrenergic receptor (β2-AR) in oral squamous cell carcinoma (OSCC) and to investigate the correlations between expression level and clinical characteristics, outcome, and patient prognosis. A total of 106 OSCC patients underwent surgical treatment at the A.C. Camargo Cancer Hospital, São Paulo, Brazil, were analyzed for clinicopathological data, treatment, tumor outcome, prognosis and immunohistochemical expression of β2-AR. The β2-AR expression was statistically analyzed relative to clinicopathological variables and survival using the Chi-square test, Kaplan-Meier curves and Cox regression model. Most OSCC (72.6%) exhibited malignant cells with strong cytoplasmatic and membranous β2-AR expression. β2-AR expression was significantly associated with alcohol (p=0.021), simultaneous consumption of alcohol and tobacco (p=0.014) and T stage (p=0.07). In addition, OSCC patients who exhibited strong β2-AR expression demonstrated a higher rate of overall survival (p=0.001) and cancer specific survival (p=0.004) compared to patients with weak/negative β2-AR expression. The Cox regression model demonstrated that strong β2-AR expression was an independent favorable prognostic factor for OSCC patients. These results suggest that the strong malignant cell β2-AR expression is a favorable prognostic factor for OSCC patients and could be used as a target for new anti-neoplastic pharmacological strategies.
